Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy [3]

Bone Marrow Transplantation

Volumn 38, Issue 12, 2006, Pages 825-828

  Ashrani, A A ^a   Gabriel, D A ^b   Gajewski, J L ^c   Jacobs Jr , D R ^d   Weisdorf, D J ^a   Key, N S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; HEMOGLOBIN; IFOSFAMIDE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; BLADDER IRRIGATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMOGLOBIN DETERMINATION; HEMORRHAGIC CYSTITIS; HUMAN; LETTER; MALE; PATIENT MONITORING; PATIENT SELECTION; PILOT STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; CYSTITIS; FACTOR VII; FEMALE; HEMORRHAGE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 33751550915     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705535     Document Type: Letter

References (9)

1. West NJ. Prevention and treatment of hemorrhagic cystitis. Pharmacotherapy 1997; 17: 696-706.
2. Seber A, Shu XO, Defor T, Sencer S, Ramsay N. Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 1999; 23: 35-40.
3. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-3864.
4. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28: 405-407.
5. Karimi M, Zakerinia M, Khojasteh HN, Ramzi M, Ahmad E. Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation. J Thromb Haemost 2004; 2: 1853-1855.
6. Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935-1944.
7. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-4223.
8. Williams JR. The fibrinolytic activity of urine. Br J Exp Pathol 1951; 32: 530-537.
9. Coggins JT, Allen TD. Insoluble fibrin clots within the urinary tract as a consequence of epsilon aminocaprioic acid therapy. J Urol 1972; 107: 647-649.